Pharmaceuticals, Biotechnology & Life Sciences

AKARI THERAPEUTICS insider buys reveal executive confidence amid a steep price drop, highlighting potential upside in its anti‑inflammatory pipeline and long‑term strategy.

Explore how MAPLIGHT THERAPEUTICS’ insider sell‑to‑cover moves reflect routine vesting rather than panic, and what the mixed buying signals mean for investors.

Danaher’s latest insider filings reveal no new trades, underscoring steady executive confidence and a strong growth trajectory for investors.

United Therapeutics’ CEO’s 10b5‑1 trades show disciplined equity management, while its oral prostacyclin pipeline and digital‑health focus promise higher value‑based reimbursement and better patient outcomes.

Gilead CFO Andrew Dickinson’s routine 3,000‑share sale shows disciplined insider liquidity amid a 26.9% YTD gain, supporting a steady, positive outlook.

Moderna insider trades reveal strategic confidence in its melanoma vaccine, blending low‑price buying with timely selling to boost liquidity and signal a bullish future.

Quanterix CTO’s insider buys reveal optimism amid falling shares—could signal an upcoming partnership or FDA approval that may lift the stock.

Mid‑cap biotech AQUESTIVE faces market‑access pressure, but its Anaphylm™ milestone could unlock premium pricing and reshape investor sentiment.

Inside AQUESTIVE’s recent insider trades reveal routine liquidity moves, not a confidence dip, while FDA approval of Anaphylm® fuels optimism for future upside.

Lisata Therapeutics strengthens governance with new finance‑savvy director, aiming to curb dilution, boost pipeline progress, and attract strategic partners amid a sharp valuation dip.